Please assess the completion status of the following clinical trial:

Trial Title: AML Therapy With Irradiated Allogeneic Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven non-M3 AML:~  * Refractory/relapsed AML OR~ * Initial diagnosis of AML in patient \>= 60 years old~* Total bilirubin =\< 1.5 times upper limit of normal (ULN) institutional limits (unless Gilbert's disease)~* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional ULN~* Cardiac left ventricular ejection fraction (LVEF) \>= 35%~* Serum creatinine =\< 1.5 mg/dl~* Any organ dysfunction thought to be secondary to disease will be considered separately and the patient will be included at the investigators discretion~* Patients must give informed consent~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 3~* Must have a potential haploidentical donor (parent, sibling, child)~* A patient is eligible for second enrollment (allo-cellular therapy) if all of the following inclusion criteria are met:~* Patient must have documented CR or CRp after 1 or 2 cycles of fludarabine + cytarabine~* Patient must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT)~* Patient must have a partially (\>= 3/6 class I antigen) human leukocyte antigen (HLA)-matched (by serology or low resolution deoxyribonucleic acid \[DNA\] testing) relative able to serve as a donor~* Patients must not have active uncontrolled infections, other medical or psychological/social conditions that might increase the likelihood of patient adverse effects or poor outcomes~* Total bilirubin \< 1.5 times upper limit of normal (ULN) institutional limits (unless Gilbert's disease)~* AST(SGOT)/ALT(SGPT) =\< 2.5 X institutional ULN~* Serum creatinine \< 2.0 mg/dl~* ECOG performance status =\< 2~* DONOR: donor must be related to patient and be partially (\>= 3/6 antigen) HLA-matched~* DONOR: donor must meet all New Brunswick Affiliated Hospitals (NBAH) requirements for hematopoietic stem cell donation, including:~* DONOR: age \>= 18 years old~* DONOR: white blood cells (WBC) 4.0-10.0 x 10\^3/mm\^3~* DONOR: platelet count 150,000 to 440,000/mm\^3~* DONOR: hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%~* DONOR: not pregnant or lactating~* DONOR: not human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B core or human T-lymphotropic virus (HTLV)-I/II seropositive; hepatitis B surface antigen (HB S ag) (-); meet other infectious disease screening criteria utilized by NBAH Blood Center~* DONOR: no uncontrolled infections, other medical or psychological/social conditions, or medications that might increase the likelihood of patient or donor adverse effects or poor outcomes~* DONOR: meet other blood bank criteria for blood product donation (as determined by NBAH Blood Center screening history and laboratory studies)~Exclusion Criteria:~* History of current or prior medical problems that the investigator feels will prevent administration of therapy or assessment of response due to excess toxicity~* Patients with known active central nervous system (CNS) leukemia will be excluded from this clinical study~* Known HIV-positive patients are excluded from the study~* Patients may not be pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard chemotherapy followed by allogenic therapy (Type: EXPERIMENTAL): INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have \>5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10\^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).